ArticleJournal of biochemical and molecular toxicology2025
Combination of 5-Fluorouracil and Thymoquinone for Enhanced Cytotoxicity, Genotoxicity and Apoptosis In Colorectal Cancer: In Vitro and In Vivo Studies.
Article in Journal of biochemical and molecular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Multicellular 3D GelMA-Based Colorectal Cancer Model for Chemotherapeutic Responses.Macromolecular bioscience · 2026Article
- MicroRNA-mediated MAPK signaling promotes isoliensinine-induced apoptosis in oral squamous cell carcinoma via the ROS-dependent mitochondrial pathway and G2 phase arrest.American journal of cancer research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Research on the effects of herbal-derived natural active substances on cancer treatment and their combination with conventional treatments has intensified. This study analyzed the cytotoxic, genotoxic, apoptotic, and anticancer effects of combined treatment with 5-Fluorouracil (5-FU) and thymoquinone (TQ) on colorectal cancer. Cytotoxicity was evaluated using the ATP assay, DNA damage was assessed through the comet assay, apoptosis was measured via acridine orange/ethidium bromide staining and annexin V-FITC dye, and the expression of proapoptotic and antiapoptotic proteins was determined by western blot analysis. Transfected LoVo cells were injected subcutaneously into nude mice, and following treatment, oxidative stress and inflammation markers were examined in blood samples, while growth factors and vascularization markers were analyzed in tissue samples. The combination therapy at low concentrations resulted in increased cytotoxicity, DNA damage, apoptosis, and intracellular reactive oxygen species (p < 0.001), while simultaneously decreasing mitochondrial membrane potential and glutathione levels (p < 0.001), in comparison to monotherapy with TQ or 5-FU. Additionally, tissue levels of TGF-β1 and VEGF-α were significantly reduced (p < 0.001). Results demonstrates that while TQ or 5-FU alone have notable anticancer effects, their combination offers greater efficacy in mitigating molecular changes in both In Vitro and In Vivo models. Future studies should focus on optimizing the formulation, understanding the molecular mechanisms, and evaluating the efficacy and safety of the TQ and 5-FU combination across different cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.